▎ 摘　　要

NOVELTY - A lesion-sites triggered release of biologically-modified polysaccharide graphene-oxide carrier (I) is obtained by connecting graphene oxide with degradable modified polysaccharide by disulfide-containing linker arm. The modified polysaccharide is linked with drug in site of the lesion using non-covalent bond. USE - Lesion-sites triggered release of biologically-modified polysaccharide graphene-oxide carrier used for pharmaceutical composition (claimed). ADVANTAGE - The lesion-sites triggered release of biologically-modified polysaccharide graphene-oxide carrier has excellent efficacy, solubility and bioavailability of drug. DETAILED DESCRIPTION - A lesion-sites triggered release of biologically-modified polysaccharide graphene-oxide carrier of formula: Gly-((CH2)n-S-S-(CH2)m)r-GO (I) is obtained by connecting graphene oxide with degradable modified polysaccharide by disulfide-containing linker arm. The modified polysaccharide is linked with drug in site of the lesion using non-covalent bond. Gly=polysaccharide molecule chain; n+m=number of the connecting arm containing alkylene; GO=graphene oxide;and r=number of connections on graphene oxide. An INDEPENDENT CLAIM is included for manufacture of polysaccharide-modified graphene carrier, which involves condensing carboxyl group-containing polysaccharide or its derivative, ethyl-1-(3-dimethylaminopropyl)carbodiimide and hydroxysuccinimide or 1-hydroxybenzotriazole, in reaction solvent and activator, dissolving graphene oxide in reaction solvent, adding the solution to the condensed solution, mixing, adding ethyl-1-(3-dimethylaminopropyl)carbodiimide and hydroxysuccinimide or 1-hydroxybenzotriazole, and condensing.